Gouws Capital LLC Purchases 400 Shares of Amgen Inc. (NASDAQ:AMGN)

Gouws Capital LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 2.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,663 shares of the medical research company’s stock after buying an additional 400 shares during the period. Amgen makes up approximately 3.6% of Gouws Capital LLC’s portfolio, making the stock its 12th biggest position. Gouws Capital LLC’s holdings in Amgen were worth $5,369,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Birchcreek Wealth Management LLC grew its holdings in shares of Amgen by 6.8% in the third quarter. Birchcreek Wealth Management LLC now owns 899 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 57 shares in the last quarter. Empirical Finance LLC grew its holdings in shares of Amgen by 2.1% in the third quarter. Empirical Finance LLC now owns 18,754 shares of the medical research company’s stock valued at $6,043,000 after acquiring an additional 380 shares in the last quarter. Check Capital Management Inc. CA grew its holdings in shares of Amgen by 2.0% in the third quarter. Check Capital Management Inc. CA now owns 3,795 shares of the medical research company’s stock valued at $1,223,000 after acquiring an additional 75 shares in the last quarter. Signature Estate & Investment Advisors LLC grew its holdings in shares of Amgen by 1.2% in the third quarter. Signature Estate & Investment Advisors LLC now owns 3,687 shares of the medical research company’s stock valued at $1,188,000 after acquiring an additional 42 shares in the last quarter. Finally, Connable Office Inc. grew its holdings in shares of Amgen by 0.5% in the third quarter. Connable Office Inc. now owns 6,972 shares of the medical research company’s stock valued at $2,246,000 after acquiring an additional 37 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 target price on shares of Amgen in a report on Tuesday, October 22nd. Truist Financial lowered Amgen from a “buy” rating to a “hold” rating and upped their target price for the company from $320.00 to $333.00 in a report on Monday, October 14th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Citigroup assumed coverage on Amgen in a research note on Thursday. They issued a “neutral” rating and a $335.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average target price of $333.57.

Amgen Trading Down 4.7 %

AMGN traded down $13.82 on Friday, hitting $282.11. 1,170,733 shares of the company were exchanged, compared to its average volume of 2,435,083. The firm has a fifty day simple moving average of $321.59 and a two-hundred day simple moving average of $318.00. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The stock has a market capitalization of $151.64 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $4.96 EPS. Sell-side analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.19%. Amgen’s dividend payout ratio is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.